

(FINAL/APPROVED)

**VIRGINIA BOARD OF PHARMACY
MINUTES OF PUBLIC HEARING TO PLACE CHEMICALS INTO SCHEDULE I AND
CONFORMING SCHEDULES TO FEDERAL SCHEDULING ACTIONS**

Wednesday, December 6, 2023

Department of Health Professions
Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233

CALL TO ORDER: A full board meeting was called to order at 9:07AM.

PRESIDING: Dale St Clair, PharmD, Chairman

MEMBERS PRESENT: Cheri Garvin, RPh
Larry Kocot, JD
Ling Yuan, PharmD
Wendy Nash, PharmD
Patricia Richards-Spruill, RPh
Kristopher Ratliff, DPh
Shannon Dowdy, PharmD
Michelle Hoffer, JD

MEMBERS ABSENT: Sarah Melton, PharmD

STAFF PRESENT: Caroline D. Juran, RPh, Executive Director
Ryan Logan, RPh, Deputy Executive Director
Ellen B. Shinaberry, PharmD, Deputy Executive Director
Annette Kelley, MS, CSAC, Deputy Executive Director
Mykl Egan, JD, Disciplinary Case Manager
Shannon Harris, Administrative and Office Specialist III
Sorayah Haden, Executive Assistant
Arne Owens, DHP Director
James Jenkins, RN, DHP Deputy Director
Erin Barrett, JD, DHP Director of Legislative and Regulatory Affairs
James Rutkowski, JD, Senior Assistant Attorney General

QUORUM: With 9 members present, a quorum was established.

The Chairman indicated the public hearing is being held to consider the placement of two chemicals into Schedule I in consultation with the Department of Forensic Science (DFS) and in accordance with subsection D of 54.1-3443. Chemicals are:

- 1-(3,5-Dimethoxy-4-propoxyphenyl)-2-propanamine (other names: 4-propoxy-3,5-DMA; 3C-P; 1-(3,5-Dimethoxy-4-propoxyphenyl)propan-2-amine), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
- 2-(5-methoxy-1H-indol-3-yl)ethanamine (other names: 5-methoxytryptamine, 5-MeOT), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

Additionally, the public hearing is being held to consider the placement of zuranolone into Schedule IV to conform with recent federal scheduling action and in accordance with subsection E of 54.1-3443.

PUBLIC COMMENT:

Robyn Weimer provided public comment on behalf of DFS. She confirmed that DFS has identified the two chemicals with hallucinogenic properties that the Board should consider placing into Schedule I.

MEETING ADJOURNED:

9:11AM



Caroline Juran,
Executive Director

3/28/2024
DATE: